3 transcripts
ACXP
Earnings call transcript
NASDAQ
2024 Q2
9 Aug 24
incidence of recurrence -- also has FDA Fast Track designation for treatment of C. difficile infection.
Additionally, we believe ibezapolstat, if approved
ACXP
Earnings call transcript
NASDAQ
2024 Q1
15 May 24
threat and calls for new classes of antibiotics for initial treatment that also have a low incidence of recurrence. Ibezapolstat is also FDA fast
ACXP
Earnings call transcript
NASDAQ
2023 Q4
18 Mar 24
as an urgent threat and there's a need for new classes of antibiotics for initial treatment, but also has a low incidence of recurrence. Ibezapolstat
- Prev
- 1
- Next